Skip to main content

Germline variation of Ribonuclease H2 genes in ovarian cancer patients


Epithelial ovarian carcinoma (EOC) is a genetically heterogeneous disease that is partly driven by molecular defects in mismatch repair (MMR) or homology-directed DNA repair (HDR). Ribonuclease H2 serves to remove mis-incorporated ribonucleotides from DNA which alleviates HDR mechanisms and guides the MMR machinery. Although Ribonuclease H2 has been implicated in cancer, the role of germline variants for ovarian cancer is unknown. In the present case-control study, we sequenced the coding and flanking untranslated regions of the RNASEH2A, RNASEH2B and RNASEH2C genes, encoding all three subunits of Ribonuclease H2, in a total of 602 German patients with EOC and of 940 healthy females from the same population. We identified one patient with a truncating variant in RNASEH2B, p.C44X, resulting in a premature stop codon. This patient had high-grade serous EOC with an 8 years survival after platinum/taxane-based therapy. Subsequent analysis of TCGA data similarly showed a significantly longer progression-free survival in ovarian cancer patients with low RNASEH2B or RNASEH2C expression levels. In conclusion, loss-of-function variants in Ribonuclease H2 genes are not common predisposing factors in ovarian cancer but the possibility that they modulate therapeutic platinum response deserves further investigation.


Ovarian cancer is a genetically heterogeneous disease [13]. The susceptibility to epithelial ovarian carcinoma can be inherited and then frequently associates with germline variants affecting mismatch repair (MMR) or homology-directed repair (HDR). Loss-of-function variants in the MMR genes MLH1, MSH2, MSH6 and PMS2 have been reported as risk factors for clear cell and endometrioid ovarian carcinomas [15, 21]. Loss-of-function variants in the HDR genes BRCA1, BRCA2, PALB2, BRIP1, RAD51C and RAD51D have been described, among others, to strongly increase the risk for serous ovarian cancer [19, 21,22,23,24,25]. In addition, evidence has been accumulated that deleterious variants in HDR genes are also predictors of therapeutic outcome [16, 18]. This seems to be related to the nature of therapeutic agents commonly used in ovarian cancer treatment, such as platinum compounds, which cause interstrand crosslinks and double-strand breaks in tumor cell DNA. The repair of this damage is dependent on HDR proficiency.

Human Ribonuclease H2 (RNAse H2) has been identified to interact with both, HDR and MMR pathways. RNase H2 is a trimeric enzyme composed of three subunits encoded by the RNASEH2A, RNASEH2B and RNASEH2C genes [12, 14]. It initiates ribonucleotide excision repair (RER) for the error-free removal of mis-incorporated ribonucleotides within a DNA strand [14]. The impairment of RNase H2 function results in the accumulation of ribonucleotides in genomic DNA. Consecutive chronic low-level DNA damage can then give rise to systemic autoimmunity in heterozygotes [10] and can result in the inflammatory Aicardi-Goutières syndrome with biallelic pathogenic variants [5]. The low-level damage in the absence of RNase H2 appears to result from an alternative TOP1-mediated processing of rNMPs which is a source of PARP1 trapping and 3′-blocking lesions [28]. If not removed properly, HDR-deficient cells are exquisitely sensitive to such lesions [2, 3, 28]. As the ribonucleotide excisions by RNase H2 may also serve to orient the mismatch repair machinery, RNase H2 defects may furthermore decrease the efficiency of MMR [9, 14, 17]. Hence, RNAse H2 impacts on repair pathways that are critical for ovarian cancer development.

Although RNase H2 has been implicated in cancer, there is little data available about germline variants of its three genes in cancer patients, and their role in ovarian cancer risk and prognosis is unclear. In the present study, we have thus sequenced the RNASEH2A, RNASEH2B and RNASEH2C genes in a case-control series of 602 German patients with EOC and of 940 healthy females from the same population.

Patients and methods


Ovarian cancer cases were included from a hospital-based case-control study which included 602 German patients who had been diagnosed with epithelial ovarian adenocarcinoma at Hannover Medical School (n = 305), the Wolfsburg Gynecology Clinics (n = 135), the University of Jena (n = 86), or partner hospitals in Bremen, Braunschweig, Burgwedel, Kassel, Oldenburg and Lüneburg (n = 76). A defined histological subtype had been assigned to 505 of the 602 patients (83.9%). The most common histology was serous (n = 381, including 276 high grade, 56 low grade, 49 no grade recorded), followed by endometrioid (n = 61), mucinous (n = 47), clear cell (n = 12), and 4 rare histological subtypes. Median age at diagnosis was 61 years, and 3% of patients reported a first-degree family history of ovarian cancer. Informed written consent was obtained from each patient. The control group consisted of 940 samples collected from unrelated healthy female blood donors at Hannover Medical School, Lower Saxony, Germany. Median age at study entry was 30 years (range 18–68 years). 95% were Germans, and all were Europeans, they were cancer-free up to the time of blood draw and were unrelated to the patients. For each study participant, DNA was isolated from peripheral white blood cells using standard phenol-chloroform extraction. The study was approved by the Ethics Commission at Hannover Medical School.

Molecular analyses

Target-specific primers for resequencing were obtained from Fluidigm Corp (San Francisco) using Fluidigm primer service program. Twenty-five primer pairs were designed and validated to cover the RNASEH2A, RNASEH2B and RNASEH2C exons in partially overlapping fragments of 250–300 bp (Supplementary Table S1). For the multiplex PCR, each genomic DNA sample was normalised to a concentration of ~ 100 ng/μl, as measured by NanoDrop photometry, and loaded onto a microfluidic 48.48 Access Array IFC (Fluidigm, San Francisco). Each primary primer pair contained the template specific sequence and a tag sequence. Each secondary primer pair contained the anti-tag sequence, a sample-specific unique barcode, and the Illumina adaptor sequence. PCR products harvested from each sample were checked through agarose gel electrophoresis to confirm uniformity of the amplicon coverage. The success rate at this stage was 92%. PCR products from cancer samples and control samples were pooled in eight libraries which were purified using AMPure magnetic beads and quantified using Quant-iT PicoGreen dsDNA Assay kit. Each library was sequenced on a separate run on a MiSeq system (Illumina, San Diego, CA). Paired end sequencing was performed using MiSeq Reagent Kit v3 (2 × 300 cycles). Sequencing quality was evident by the Q30 scores (one error in 1000 bp sequence) and a cutoff of 85% sequence with Q30 score was used as an indication of successful sequencing.

The RNASEH2B variant p.C44X was additionally amplified from germline DNA of the patient and a control using the primers 5′- ACAGGGTAAAGTAAGGTGAG - 3′ and 5′- GTGTATATACTCATTAGCCAC - 3′ and was validated through Sanger sequencing using BigDye chemistry and capillary electrophoresis on a SeqStudio Genetic Analyser (Applied Biosystems).


Sequencing data were analysed with NextGENe 2nd Generation Sequencing Software v.2.4.2 (SoftGenetics, Philadelphia, USA). Briefly, fastq.qz files were aligned to RNASEH2A, RNASEH2B and RNASEH2C gbk files from the human reference sequences of the GRCh37.p13 Assembly (NC_000019, 12,912,863..12924462 for RNASEH2A, NC_000013, 51,483,814..51544596 for RNASEH2B, NC_000011 complement (65,485,144..65488409) for RNASEH2C; Alignment was performed with a required matching of over 80% within more than 30 bases. We filtered out variants if the proportion of variant calls was below 25% or if the total number of variant calls was below n = 5. The average number of sequence variants detected in cases was very similar to those detected in controls (cases: median 187 variants (range 98–404); controls: median 192 variants (range 74–247)). The p.C44X variant in RNASEH2B was validated by conventional Sanger sequencing using BigDye chemistry. Sequence variants were checked for previously published reports in the Genome Aggregation database ( and were annotated with Reference SNP cluster IDs from the NCBI SNP database ( Splice site analyses were performed using the publicly available MaxEntScan tool from Yeo and Burge ( [8]. Missense variants were assessed for deleteriousness using Mutation Taster ( Somatic variations of RNASEH2B in the Pan Cancer cohort of the TCGA database (4742 tumors, including 316 ovarian tumors) were accessed via the TumorPortal (


Genetic association analyses of selected variants were performed using Fisher’s exact test at 2 df, and p-values above α = 0.05 were considered non-significant. Survival analysis of TCGA data for ovarian cancer patients was performed using an online Kaplan-Meier plotter (KMplotter, [11]. We examined gene expression levels using default analysis conditions, with auto-select best cut-off and for all datasets comprising up to 1435 patients. The Affymetrix probes used were 203022_at for RNASEH2A, 229210_at for RNASEH2B and 227543_at for RNASEH2C. Because we analysed three genes in three patient groups (overall, serous histology, high-grade), p-values ≤0.005 were considered significant after Bonferroni correction for multiple testing. Hazard ratios are expressed for high-expression relative to low-expression group. We examined RNASEH2B expression levels in the Human Protein Atlas database ( [26] for 373 ovarian cancer patients using default analysis conditions, with auto-select best cut-off (FPKM 3.5). We compared 82 patients with high expression and 291 patients with low expression and derived a log-rank P value for the Kaplan-Meier plot of patient survival in these two groups.


We successfully sequenced the coding exons and their flanking intronic and untranslated regions of the RNASEH2A, RNASEH2B and RNASEH2C genes in a case-control series of 602 German patients with histologically confirmed EOC and of 940 healthy German females. The coding variants identified in this series are summarized in Table 1. In RNASEH2A, eight rare missense variants were detected of which three affected conserved residues and were predicted to be pathogenic (p.D2Y/p.L3P, p.G132D, p.R239C). However, these variants were restricted to single females and no overall enrichment was observed in cases compared to controls. In RNASEH2B, one truncating variant, p.C44X, was detected in a single ovarian cancer patient (Fig. 1a). Clinical features of this patient will be described further below. We also noted a potential frameshift variant, c.827dupA, in one control. However, the frameshift affects only isoform 1 and is absent/intronic in isoform 2, suggesting that it can be circumvented through means of alternative splicing (Supplementary Fig. S1). Again, no significant overall enrichment was observed for those rare missense variants that affected conserved residues and were predicted to be pathogenic (p.A177T, p.S217P, p.K248N, p.T263A). In RNASEH2C, we did not observe any missense or truncating variants. One of three synonymous variants, c.468G > T, affected the last base of an exon and was predicted to mildly disturb the splice donor site (MaxEntScan score 7.39 compared to 10.49 for wildtype). However, this variant was not significantly enriched in cases versus controls (OR 1.96, p = 0.32).

Table 1 Missense and splice site variants in RNASEH2A, RNASEH2B and RNASEH2C
Fig. 1

a. Sequencing of RNASEH2B variant p.C44X. Figure legend: Validation of RNASEH2B variant p.C44X through Sanger sequencing in a wildtype control (top) and the index ovarian cancer patient (bottom). The sense strand is shown. Heterozygosity for a T > A transversion was confirmed, changing the cysteine codon TGT to the stop codon TGA. b. Progression-free survival of ovarian cancer patients in relation to RNASEH2B levels. Figure legend: Progression-free survival of ovarian cancer patients in the TCGA database for patients with high versus low RNA levels of RNASEH2B. The Affymetrix probe 229210_at specific for RNASEH2B was used, and patients were stratified using auto-select best cut-off in KMplotter ( [11]

We more thoroughly inspected the clinical records of the single patient who was heterozygous for the RNASEH2B*p.C44X truncating variant. This patient had no family history of cancer and had been negative for pathogenic variants after sequencing the BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PTEN and MMR genes. She had been diagnosed by the age of 67 years with a high-grade serous ovarian carcinoma of FIGO stage IIIc, pT3c, and with positive nodal status though no detectable metastases. She received standard therapy of six cycles carboplatinum/taxol. Six years later, she presented with a late recurrence and with metastases in breast and abdominal wall. Her cancer then progressed despite nine cycles carboplatinum monotherapy followed by six cycles of treosulfan, three cycles of Caelyx and finally tamoxifen therapy. The patient died from her cancer by the age of 75, eight years after the initial diagnosis. The long interval between her primary diagnosis and the recurrence was markedly higher than the median progression-free survival of HGSOC patients at this hospital, suggesting that her RNASEH2B truncation could have been of beneficial effect.

We aimed to test this hypothesis further using gene expression data from previous ovarian cancer cohorts. In fact, an in silico analysis of publicly available TCGA data using KMplotter provided supportive evidence for an improved progression-free survival in patients with reduced RNASEH2B expression (HR 1.53, 95% CI 1.27–1.86, p = 9.7 × 10− 6; Fig. 1b). The beneficial effect was largely restricted to patients with full success of surgery (HR 1.84, 95% CI 1.31–2.57, p = 3.1 × 10− 4 with optimal debulking; HR 1.17, 95% CI 0.85–1.60, p = 0.34 with suboptimal debulking). When the analysis was restricted to patients with platinum-taxane therapy, there was a significantly better progression-free survival for the low-expression cohort in patients with optimal debulking (HR 1.78, 95% CI 1.21–2.61, p = 2.8 × 10− 3). Median overall survival also was increased from 38 months in the high-expression cohort to 48 months in the low-expression cohort (HR 1.28, 95% CI 1.00–1.49, p = 0.05), and the survival advantage was again restricted to patients with optimal debulking (HR 1.65, 95% CI 1.08–2.51, p = 0.02). A similar result was obtained from the analysis of 373 ovarian cancers listed in The Human Protein Atlas [26] where patients with low RNASEH2B levels tended to have a longer survival than patients with high RNASEH2B levels (5-year-survival 33 months vs. 28 months, p = 0.01). When testing the other RNAse H2 genes with KMplotter, a decreased level of RNASEH2A showed no benefit (HR 0.86, 95% CI 0.78–0.98, p = 0.02 for all patients; HR 0.84, 95% CI 0.69–1.02 for patients with optimal debulking p = 0.07), whereas the analysis of RNASEH2C yielded results similar to RNASEH2B, indicating an improved progression-free survival in patients with reduced RNASEH2C levels (HR 1.55, 95% CI 1.28–1.87, p = 5.4 × 10− 6 for all patients; HR 1.80, 95% CI 1.30–2.89, p = 3.2 × 10− 4 for patients with optimal debulking).


Faulty rNTP insertions into the human genome are a common event during DNA replication, estimated to occur at about 1 in 6500 nucleotides [17]. As they have detrimental impact on DNA structure and on replication fork progression, they need to be removed by RNase H1 (for stretches of ribonucleotides) or RNase H2 (for single ribonucleotides) [14]. Human RNase H2 shows strong conservation and comprises RNASEH2A, the catalytic subunit, as well as RNASEH2B and RNASEH2C [4, 14]. Loss of any of its subunits renders the enzyme complex inactive [12, 14]. This results in low level of DNA damage which probably explains the association of RNase H variants with inflammatory disorders but also might be expected to support cancer development. However, the role of RNase H2 in hereditary cancer has been difficult to assess because most patients with Aicardi-Goutières syndrome and pathogenic RNase H2 germline variants have a short lifespan [5]. Nevertheless, it has been proposed that genome instability through RNase H2 impairment upon p53 loss can lead to oncogenic rearrangements and cancer development [14]. Specifically RNASEH2B deletions were reported in 57% of chronic lymphocytic leukemias and 36% of aggressive prostate cancers [28]. Interestingly, an exome sequencing study of 491 cases has proposed RNASEH2B as a candidate gene for prostate cancer [20]. A possible role for ovarian cancer had not been investigated. Data mining via the TumorPortal indicates four truncating or splice variants of RNASEH2B in epithelial cancers (2 in lung adenocarcinoma, 1 in melanoma and 1 in endometrial carcinoma) but none among 316 ovarian cancers.

In the present study, we have aimed to systematically assess the mutational spectrum of the RNase H2 subunit genes RNASEH2A, RNASEH2B and RNASEH2C in a relatively large case-control series of 602 German patients with EOC and 940 healthy German females to elucidate their possible contribution to ovarian cancer risk and prognosis. Only one patient was found to harbor a bona fide loss-of-function variant, p.C44X in RNASEH2B. This variant is listed in gnomAD with a single heterozygote out of 125,644 individuals sequenced, confirming that it is very rare in the general population. Further inspection of our patient revealed a particularly long survival after platinum-based therapy despite some unfavorable prognostic parameters such as high grade serous histology and nodal-positive status. It is possible that the RNASEH2B truncating variant modifies survival in such patients. Given the importance of HDR under conditions of rNMP accumulation and PARP1 trapping [28], RNase H2 impairment may assist chemotherapy efficiency when HDR mechanisms are overloaded. Recent evidence indicates that RNase H2 deficiency overall inhibits the exonucleolytic resection of DNA break ends [6], and the same may happen in single-stranded gap filling during or after DNA replication [1, 27]. In line with the latter, RNASEH2B is also synthetically lethal with ATR inhibition [27]. Alternatively, RNase H2 deficiency may amplify the mutagenic load in an indirect manner, such as by decreasing the efficiency of MMR [9, 14, 17]. It is also possible that a cytotoxic T-cell response is activated by the absence of RNase H2 which may contribute to the suppression of tumor progression. Such a mechanism has been suggested for RNASEH2C as a metastasis susceptibility gene in breast cancer [7].

Consistent with a prognostic role of RNAse H2 in ovarian cancer, our mining of the TCGA database revealed a markedly improved progression-free survival in ovarian cancer patients with reduced RNASEH2B expression at a significance level of p < 10− 5. A similar result was obtained for RNASEH2C, which encodes the other regulatory subunit, though not for RNASEH2A encoding the catalytic core unit. The prognostic impact of RNASE2B and RNASE2C levels was maintained significant in the subset of patients with optimal debulking and platinum/taxane-based therapy. If confirmed by other studies, RNASEH2B and RNASEH2C could emerge as promising targets to improve the outcome of this standard treatment.

In summary, we have shown that pathogenic germline variants in the genes encoding the RNase H2 complex are uncommon in German ovarian cancer patients. We report one patient with a truncating variant in RNASEH2B whose longer survival appears consistent with the association of RNASEH2B mRNA levels and prolonged survival in previously published ovarian cancer cohorts. Further studies will be required to elucidate how RNase H2 function and regulation affects the prognosis of patients with different ovarian cancer subtypes and treatment regimens.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


  1. 1.

    Ait Saada A, Lambert SAE, Carr AM. Preserving replication fork integrity and competence via the homologous recombination pathway. DNA Repair (Amst). 2018; 71: 135–147. doi: Epub 2018 Aug 25. PMID: 30220600; PMCID: PMC6219450.

  2. 2.

    Allen-Soltero S, Martinez SL, Putnam CD, Kolodner RD. A Saccharomyces cerevisiae RNase H2 interaction network functions to suppress genome instability. Mol Cell Biol. 2014; 34(8):1521–1534. doi: Epub 2014 Feb 18. PMID: 24550002; PMCID: PMC3993591.

  3. 3.

    Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D. Endogenous DNA 3′ Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease. Mol Cell. 2020; 78(6): 1152–1165.e8. doi: Epub 2020 Jun 8. PMID: 32516598; PMCID: PMC7340272.

  4. 4.

    Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, Ali M, Semple C, Aicardi J, Babul-Hirji R, Baumann C, Baxter P, Bertini E, Chandler KE, Chitayat D, Cau D, Déry C, Fazzi E, Goizet C, King MD, Klepper J, Lacombe D, Lanzi G, Lyall H, Martínez-Frías ML, Mathieu M, McKeown C, Monier A, Oade Y, Quarrell OW, Rittey CD, Rogers RC, Sanchis A, Stephenson JB, Tacke U, Till M, Tolmie JL, Tomlin P, Voit T, Weschke B, Woods CG, Lebon P, Bonthron DT, Ponting CP, Jackson AP. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet. 2006; 38(8): 910–916. doi: Epub 2006 Jul 16. PMID: 16845400.

  5. 5.

    Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, Oojageer A, Anderson B, Pizzino A, Helman G, Abdel-Hamid MS, Abdel-Salam GM, Ackroyd S, Aeby A, Agosta G, Albin C, Allon-Shalev S, Arellano M, Ariaudo G, Aswani V, Babul-Hirji R, Baildam EM, Bahi-Buisson N, Bailey KM, Barnerias C, Barth M, Battini R, Beresford MW, Bernard G, Bianchi M, Billette de Villemeur T, Blair EM, Bloom M, Burlina AB, Carpanelli ML, Carvalho DR, Castro-Gago M, Cavallini A, Cereda C, Chandler KE, Chitayat DA, Collins AE, Sierra Corcoles C, Cordeiro NJ, Crichiutti G, Dabydeen L, Dale RC, D'Arrigo S, De Goede CG, De Laet C, De Waele LM, Denzler I, Desguerre I, Devriendt K, Di Rocco M, Fahey MC, Fazzi E, Ferrie CD, Figueiredo A, Gener B, Goizet C, Gowrinathan NR, Gowrishankar K, Hanrahan D, Isidor B, Kara B, Khan N, King MD, Kirk EP, Kumar R, Lagae L, Landrieu P, Lauffer H, Laugel V, La Piana R, Lim MJ, Lin JP, Linnankivi T, Mackay MT, Marom DR, Marques Lourenço C, McKee SA, Moroni I, Morton JE, Moutard ML, Murray K, Nabbout R, Nampoothiri S, Nunez-Enamorado N, Oades PJ, Olivieri I, Ostergaard JR, Pérez-Dueñas B, Prendiville JS, Ramesh V, Rasmussen M, Régal L, Ricci F, Rio M, Rodriguez D, Roubertie A, Salvatici E, Segers KA, Sinha GP, Soler D, Spiegel R, Stödberg TI, Straussberg R, Swoboda KJ, Suri M, Tacke U, Tan TY, te Water Naude J, Wee Teik K, Thomas MM, Till M, Tonduti D, Valente EM, Van Coster RN, van der Knaap MS, Vassallo G, Vijzelaar R, Vogt J, Wallace GB, Wassmer E, Webb HJ, Whitehouse WP, Whitney RN, Zaki MS, Zuberi SM, Livingston JH, Rozenberg F, Lebon P, Vanderver A, Orcesi S, Rice GI. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A(2):296–312. doi: Epub 2015 Jan 16. PMID: 25604658; PMCID: PMC43822.

  6. 6.

    Daley JM, Tomimatsu N, Hooks G, et al. Specificity of end resection pathways for double-strand break regions containing ribonucleotides and base lesions. Nat Commun. 2020;11:3088

    CAS  Article  Google Scholar 

  7. 7.

    Deasy SK, Uehara R, Vodnala SK, Yang HH, Dass RA, Hu Y, Lee MP, Crouch RJ, Hunter KW. Aicardi-Goutières syndrome gene Rnaseh2c is a metastasis susceptibility gene in breast cancer. PLoS Genet. 2019; 15(5):e1008020. doi: PMID: 31125342; PMCID: PMC6553800.

  8. 8.

    Eng L, Coutinho G, Nahas S, Yeo G, Tanouye R, Babaei M, Dörk T, Burge C, Gatti RA. Nonclassical splicing mutations in the coding and noncoding regions of the ATM gene: maximum entropy estimates of splice junction strengths. Hum Mutat. 2004;23(1):67–76. 14695534.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Ghodgaonkar MM, Lazzaro F, Olivera-Pimentel M, Artola-Borán M, Cejka P, Reijns MA, Jackson AP, Plevani P, Muzi-Falconi M, Jiricny J. Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair. Mol Cell. 2013; 50(3):323–332. doi: Epub 2013 Apr 18. PMID: 23603115; PMCID: PMC3653069.

  10. 10.

    Günther C, Kind B, Reijns MA, Berndt N, Martinez-Bueno M, Wolf C, Tüngler V, Chara O, Lee YA, Hübner N, Bicknell L, Blum S, Krug C, Schmidt F, Kretschmer S, Koss S, Astell KR, Ramantani G, Bauerfeind A, Morris DL, Cunninghame Graham DS, Bubeck D, Leitch A, Ralston SH, Blackburn EA, Gahr M, Witte T, Vyse TJ, Melchers I, Mangold E, Nöthen MM, Aringer M, Kuhn A, Lüthke K, Unger L, Bley A, Lorenzi A, Isaacs JD, Alexopoulou D, Conrad K, Dahl A, Roers A, Alarcon-Riquelme ME, Jackson AP, Lee-Kirsch MA. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest. 2015; 125(1):413–424. doi: Epub 2014 Dec 15. PMID: 25500883; PMCID: PMC4382239.

  11. 11.

    Győrffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients. Endocr Cancer. 2012;19(2):197–208.

    Article  Google Scholar 

  12. 12.

    Jeong HS, Backlund PS, Chen HC, Karavanov AA, Crouch RJ. RNase H2 of Saccharomyces cerevisiae is a complex of three proteins. Nucleic Acids Res. 2004; 32(2):407–414. doi: Erratum in: Nucleic Acids Res. 2004 Feb 24;32(4):1616. PMID: 14734815; PMCID: PMC373335.

  13. 13.

    Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol 2017;147(3):705–713. doi: Epub 2017 Oct 18. PMID: 29054568.

  14. 14.

    Kellner V, Luke B. Molecular and physiological consequences of faulty eukaryotic ribonucleotide excision repair. EMBO J. 2020; 39(3):e102309. doi: Epub 2019 Dec 12. PMID: 31833079; PMCID: PMC6996501.

  15. 15.

    Ketabi Z, Bartuma K, Bernstein I, Malander S, Grönberg H, Björck E, Holck S, Nilbert M. Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 2011;121(3):462–465. doi: Epub 2011 Mar 9. PMID: 21388660.

  16. 16.

    Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137–54.

    CAS  Article  Google Scholar 

  17. 17.

    Lujan SA, Williams JS, Clausen AR, Clark AB, Kunkel TA. Ribonucleotides are signals for mismatch repair of leading-strand replication errors. Mol Cell. 2013; 50(3):437–443. doi: Epub 2013 Apr 18. PMID: 23603118; PMCID: PMC3658170.

  18. 18.

    Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20(3):764–775. doi: Epub 2013 Nov 15. PMID: 24240112; PMCID: PMC3944197.

  19. 19.

    Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G; AOCS Study Group, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Dürst M, Hillemanns P; Ovarian Cancer Association Consortium, Odunsi K, Whittemore AS, Karlan BY, Dörk T, Goode EL, Menon U, Jacobs IJ, Antoniou AC, Pharoah PD, Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst. 2015; 107(11):djv214. doi: PMID: 26315354; PMCID: PMC4643629.

  20. 20.

    Schaid DJ, Mcdonnell SK, FitzGerald LM, Derycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, Nguyen-Dumont T, Cancel-Tassin G, Cussenot O, Whittemore AS, Sieh W, Ioannidis NM, Hsieh CL, Stanford JL, Schleutker J, Cropp CD, Carpten J, Hoegel J, Eeles R, Kote-Jarai Z, Ackerman MJ, Klein CJ, Mandal D, Cooney KA, Bailey-Wilson JE, Helfand B, Catalona WJ, Wiklund F, Riska S, Bahetti S, Larson MC, Cannon Albright L, Teerlink C, Xu J, Isaacs W, Ostrander EA, Thibodeau SN. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. Eur Urol. 2020:S0302–2838(20)30614-X. doi: Epub ahead of print. PMID: 32800727.

  21. 21.

    Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014; 23(17):4703–4709. doi: Epub 2014 Apr 12. PMID: 24728189; PMCID: PMC4119409.

  22. 22.

    Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015; 33(26):2901–2907. doi: Epub 2015 Aug 10. PMID: 26261251; PMCID: PMC4554751.

  23. 23.

    Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, Rossing MA, Duerst M, Dörk T, Bogdanova NV, Modugno F, Moysich K, Odunsi K, Ness R, Karlan BY, Lester J, Jensen A, Krüger Kjaer S, Høgdall E, Campbell IG, Lázaro C, Pujara MA, Cunningham J, Vierkant R, Winham SJ, Hildebrandt M, Huff C, Li D, Wu X, Yu Y, Permuth JB, Levine DA, Schildkraut JM, Riggan MJ, Berchuck A, Webb PM, Group OS, Cybulski C, Gronwald J, Jakubowska A, Lubinski J, Alsop J, Harrington P, Chan I, Menon U, Pearce CL, Wu AH, de Fazio A, Kennedy CJ, Goode E, Ramus S, Gayther S, Pharoah P (2020) Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer. J Med Genet. Advanced online Jun 16, 2020:jmedgenet-2019-1067.

  24. 24.

    Subramanian DN, Zethoven M, McInerny S, Morgan JA, Rowley SM, Lee JEA, Li N, Gorringe KL, James PA, Campbell IG. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. Nat Commun. 2020; 11(1):1640. doi: PMID: 32242007; PMCID: PMC7118163.

  25. 25.

    Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res. 2020; 13(1):50. doi: PMID: 32359370; PMCID: PMC7196220.

  26. 26.

    Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. 28818916.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019; 38(14):2451–2463. doi: Epub 2018 Dec 7. PMID: 30532030; PMCID: PMC6450769.

  28. 28.

    Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature. 2018; 559(7713):285–289. doi: PMID: 29973717; PMCID: PMC6071917.

Download references


We thank all patients and their clinicians for their participation in this study, and Franca Victoria Seidensticker for her assistance in sequencing.


This work was supported by the German Research Foundation (Do 761/15–1). Open Access funding enabled and organized by Projekt DEAL.

Author information




RP took part in the preparation, amplification and targeted sequencing of DNA samples, in the bioinformatics analyses and in writing the manuscript. PS took part in the amplification and targeted sequencing of DNA samples. LS took part in the preparation, amplification and Sanger sequencing of DNA samples. RG performed next-generation sequencing and quality controls. MD, PH, TP and CL contributed patient samples and clinical data. TD designed the study, took part in bioinformatic analyses of targeted sequencing results and survival data, and drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Thilo Dörk.

Ethics declarations

Ethics approval and consent to participate

This work was approved by the Ethics Committee at Hannover Medical School. All study participants gave informed consent to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Figure 1:

Identified missense and truncating variants of RHASEH2B.

Additional file 2: Supplementary Table S1:

Primer sequences for RNASEH2A, RNASEH2B and RNASEH2C amplification.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Polaczek, R., Schürmann, P., Speith, LM. et al. Germline variation of Ribonuclease H2 genes in ovarian cancer patients. J Ovarian Res 13, 146 (2020).

Download citation


  • RNase H2
  • Ribonucleotide excision repair
  • Homologous recombination
  • MMR deficiency
  • Platinum resistance
  • Epithelial ovarian carcinoma